This is a phase Ⅲ multicenter, open-label, follow-up study, to assess the safety and efficacy of certolizumab pegol (CZP) as additional medication to methotrexate (MTX), in patients with active rheuma...

Condition : Psoriasis Intervention : Radiation: UVB-311nm radiation Sponsor : Medical University of Graz Recruiting - verified October 2013

Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol (CZP) in subjects with adult onset active and progres...

Condition : Psoriasis Intervention : Radiation: UVB-311nm radiation Sponsor : Medical University of Graz Recruiting - verified August 2011

The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of certolizumab pegol (CZP) in subjects with active axi...

Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol (CZP) in subjects with adult onset active and progres...

Condition : Psoriasis Intervention : Radiation: UVB-311nm radiation Sponsor : Medical University of Graz Recruiting - verified August 2011

The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of certolizumab pegol (CZP) in subjects with active axi...

Condition : Healthy Interventions : Drug: PF-04308515; Drug: Placebo; Drug: PF-04308515 Tablet Sponsor : Pfizer Completed - verified July 2011

Condition : Lupus Arthritis Interventions : Drug: Laquinimod; Drug: Laquinimod; Other: Placebo Sponsor : Teva Pharmaceutical Industries Recruiting - verified August 2011